NASDAQ
02.06.26 | 22:00
15,340 US-Dollar
-5,37 % -0,870
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Morocco and Finland Launch Business Council in Helsinki as Tazi Makes First European Outing as CGEM President | 2 | North Africa Post | ||
| CULLINAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 19.05. | Stifel reiterates Cullinan Oncology stock rating on trial data | 6 | Investing.com | ||
| 19.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia | 216 | GlobeNewswire (Europe) | Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan... ► Artikel lesen | |
| 18.05. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.05. | Cullinan Therapeutics, Inc.: Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress | 1 | GlobeNewswire (USA) | ||
| 15.05. | Tazi and Bachiri Elected to Lead CGEM with 91.5% of the Vote | 1 | North Africa Post | ||
| 07.05. | CGEM Forum Reveals Only 6,000 Moroccan Firms Export, a Path to Change chartered | 2 | North Africa Post | ||
| 07.05. | Cullinan Therapeutics GAAP EPS of -$0.75 | 2 | Seeking Alpha | ||
| 07.05. | Cullinan Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Cullinan Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 24.03. | Gilead-Deal untermauert Potenzial: Clear Street bestätigt Kaufempfehlung für Cullinan Oncology | 18 | Investing.com Deutsch | ||
| 24.03. | Clear Street reiterates Cullinan Oncology stock rating on Gilead deal validation | 7 | Investing.com | ||
| 10.03. | Cullinan Therapeutics: Q4 Earnings Insights | 3 | Benzinga.com | ||
| 10.03. | Stifel raises Cullinan Oncology stock price target on autoimmune progress | 2 | Investing.com | ||
| 10.03. | Cullinan Therapeutics GAAP EPS of -$0.77 misses by $0.05 | 1 | Seeking Alpha | ||
| 10.03. | Cullinan Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.03. | Cullinan Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Cullinan Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.02. | Guggenheim stuft Cullinan Oncology mit "Kaufen" ein und sieht 151 % Kurspotenzial | 10 | Investing.com Deutsch | ||
| 02.02. | Guggenheim initiates Cullinan Oncology stock with Buy rating, $30 target | 9 | Investing.com |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REGENXBIO | 6,304 | +2,60 % | Stifel reiterates Buy rating on Regenxbio stock ahead of trial data | ||
| DBV TECHNOLOGIES | 3,018 | -6,10 % | DBV Technologies S.A.: Combined General Meeting of June 3, 2026 | Châtillon, France, May 13, 2026
Combined General Meeting of June 3, 2026
Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting
DBV Technologies... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 6,080 | -1,62 % | Sagimet Biosciences Inc.: Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH | ||
| CABALETTA BIO | 3,675 | +0,14 % | Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update | Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose of rese-cel in the RESET-PV- study presented today at ASGCT 2026 Annual Meeting along with initial... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,675 | -3,32 % | Taysha Gene Therapies, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 258,08 | -23,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,860 | 0,00 % | Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments | ||
| ERASCA | 13,480 | -2,46 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 78,71 | -0,74 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,690 | +11,67 % | Relay Therapeutics Shares Jump 18% | ||
| COGENT BIOSCIENCES | 32,760 | -6,29 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| QIAGEN | 30,705 | -0,36 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 37,300 | +9,19 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,505 | -2,16 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 10,690 | -15,89 % | Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA (darolutamide) in Metastatic Castration-Resistant Prostate Cancer | Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026First clinical collaboration for OP-3136; results... ► Artikel lesen |
CULLINAN THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 15,340 Euro und damit -5,37 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CULLINAN THERAPEUTICS INC finden Sie auf Wallstreet Online.